Cantargia AB (SE:CANTA)
:CANTA
Want to see SE:CANTA full AI Analyst Report?
Top Page
Cantargia AB
(CANTA)
Select Model
Select Model
Rating:65Neutral
Price Target:
kr2.50
▼(-38.57% Downside)
Action:Reiterated
Date:05/30/26
Score is supported primarily by improved TTM profitability/cash generation and a low P/E valuation. These positives are moderated by weak technicals (below key moving averages and negative MACD) and the risk that recent financial strength is not yet proven to be consistent given prior years of zero revenue and losses.
Positive Factors
Strong TTM cash generation
Sustained operating and free cash flow in the trailing twelve months indicates the company can self-fund near-term development milestones and absorb R&D spending volatility. This cash convertibility supports project continuity and reduces immediate refinancing dependency for 2–6 months.
Negative Factors
Revenue and profit volatility
Historic multi-year revenue absence followed by a sudden TTM spike suggests earnings may be driven by one-off milestones or licensing events. This episodic nature weakens predictability of future cash flows and complicates planning for sustained R&D or commercial scaling.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong TTM cash generation
Sustained operating and free cash flow in the trailing twelve months indicates the company can self-fund near-term development milestones and absorb R&D spending volatility. This cash convertibility supports project continuity and reduces immediate refinancing dependency for 2–6 months.
Read all positive factors
Cantargia AB (CANTA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr725.95M
Dividend YieldN/A
Average Volume (3M)1.42M
Price to Earnings (P/E)3.4
Beta (1Y)0.74
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.65
Shares Outstanding248,611,650
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.91
Price to Sales (P/S)3.28
P/FCF Ratio6.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr14.00Price Target Upside243.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.42
Revenue Forecast (FY)kr2.93M
Cantargia AB Business Overview & Revenue Model
Company Description
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP...
How the Company Makes Money
Cantargia makes money primarily by raising capital to fund research and development (e.g., share issuances) rather than through recurring product sales, as it does not have publicly disclosed marketed products generating significant commercial rev...
Cantargia AB Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
74
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 317.21M | 316.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 315.37M | 316.70M | -3.44M | -3.45M | -3.69M | -3.45M |
| EBITDA | 164.87M | 157.66M | -165.05M | -284.31M | -368.12M | -363.06M |
| Net Income | 160.93M | 146.97M | -161.65M | -280.03M | -371.81M | -366.50M |
Balance Sheet | ||||||
| Total Assets | 267.84M | 296.66M | 170.43M | 223.71M | 474.80M | 600.24M |
| Cash, Cash Equivalents and Short-Term Investments | 258.03M | 281.82M | 33.04M | 194.75M | 426.67M | 559.39M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 33.89M | 30.78M | 54.12M | 54.97M | 85.11M | 67.50M |
| Stockholders Equity | 233.95M | 265.88M | 116.30M | 168.74M | 389.68M | 532.75M |
Cash Flow | ||||||
| Free Cash Flow | 157.57M | 149.66M | -162.75M | -286.66M | -366.00M | -346.83M |
| Operating Cash Flow | 158.09M | 150.13M | -162.75M | -286.66M | -358.92M | -346.44M |
| Investing Cash Flow | -12.52M | -472.00K | 55.00M | 182.09M | 67.88M | -102.43M |
| Financing Cash Flow | -3.00M | 103.86M | -1.07M | 54.68M | 223.93M | 3.00K |
Cantargia AB Technical Analysis
Negative
4.07
Price Trends
3.71
Negative
4.34
Negative
3.74
Negative
Market Momentum
-0.31
Positive
17.75
Positive
19.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CANTA, the sentiment is Negative. The current price of 4.07 is above the 20-day moving average (MA) of 3.30, above the 50-day MA of 3.71, and above the 200-day MA of 3.74, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 17.75 is Positive, neither overbought nor oversold. The STOCH value of 19.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CANTA.
Cantargia AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:CANTA
Cantargia AB
2.18
0.91
71.38%
SE:ONCO
Oncopeptides AB
1.81
0.40
28.19%
DE:8F8
SynAct Pharma AB
1.49
0.12
8.76%
DE:5LH0
Guard Therapeutics International AB
0.03
-1.55
-97.92%
DE:1YG0
Immunicum AB
0.53
0.06
13.52%
Cantargia AB Corporate Events
Cantargia Raises Up to SEK 199 Million to Advance Nadunolimab Oncology Pipeline
May 28, 2026
Cantargia AB has launched a SEK 124 million rights issue and secured a loan agreement of up to SEK 75 million from Fenja Capital to strengthen its balance sheet and fund key clinical initiatives. Existing shareholders receive preferential rights t...
Cantargia Raises Funds to Expand Nadunolimab Strategy in Cancer and Blood Disorders
May 28, 2026
Cantargia AB plans to host a webcast on June 1 to outline a rights issue and loan agreement designed to bolster its finances and support an expanded clinical development strategy. The capital injection aims to fund additional work on nadunolimab, ...
Cantargia AGM Backs Equity Incentives and Expands Capital Raising Mandate
May 21, 2026
Cantargia AB’s annual general meeting approved the 2025 financial statements, decided to retain all earnings without distributing a dividend, and discharged the board and CEOs from liability, while confirming a five-member board with Magnus ...
Cantargia Highlights Pipeline Progress in Q1 2026 Interim Report
May 19, 2026
Cantargia AB has released its interim report for January to March 2026, outlining operational progress across its pipeline of targeted antibody-based drug candidates. The report highlights developments in key programs such as nadunolimab, CAN14, C...
Cantargia to Present Q1 2026 Interim Results in Audiocast and Teleconference
May 6, 2026
Cantargia AB will publish its interim report for the first quarter of 2026 on May 19 and will host an English-language audiocast and teleconference the same day, where CEO Hilde Steineger and CFO Patrik Renblad will present the results and take qu...
Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
Apr 27, 2026
Cantargia has reported early data from an ongoing Phase 1b/2a trial of its IL1RAP-targeting antibody nadunolimab in high-risk myelodysplastic syndrome and acute myelogenous leukemia, where it is combined with azacitidine, or azacitidine plus venet...
Cantargia Showcases New Nadunolimab Trial in Hard-to-Treat Colorectal Cancer at AACR 2026
Apr 17, 2026
Cantargia will present the design and supporting preclinical data for an investigator-initiated phase 1b/2 trial of its IL1RAP-targeting antibody nadunolimab combined with the anti-PD-1 drug toripalimab in chemotherapy-refractory metastatic micros...
Cantargia convenes 2026 AGM with focus on continuity in board
Apr 17, 2026
Cantargia AB has called its annual general meeting for 21 May 2026 in Lund, Sweden, offering shareholders the option to participate either in person or via digital postal voting. Shareholders must be registered with Euroclear Sweden by 12 May and ...
Cantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer
Mar 18, 2026
Cantargia has reported new preclinical data showing that a murine surrogate of its anti-IL1RAP antibody nadunolimab can reduce immunosuppression in metastatic colorectal cancer, particularly when combined with an anti-PD-1 immune-checkpoint inhibi...
Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference
Mar 5, 2026
Cantargia AB will engage in one-on-one investor and partner meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 16, 2026, as part of its outreach to the life sciences investment community. Participation in this speci...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.